June 2020

Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million (USD$4.9 million) in an oversubscribed Series A2 investment round. GPN Vaccines has created...

Protecting children and adults from the world’s foremost bacterial pathogen